comparemela.com

Latest Breaking News On - Dawson james - Page 5 : comparemela.com

22nd Century Group, Inc. (NASDAQ:XXII) Q4 2023 Earnings Call Transcript

Operator: Welcome to the 22nd Century Group Fourth Quarter 2023 Conference Call and Webcast.

Oregon
United-states
North-carolina
Maryland
Grass-valley
Switzerland
Swiss
Jeremi-smith
Matt-kreps
Dawson-james
Remington-smith
Jim-mcilree

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Significant Increase in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 967,000 shares, a growth of 56.9% from the February 29th total of 616,200 shares. Approximately 1.2% of the shares of the company are short sold. […]

Zembrace-symtouch
Dawson-james
Renaissance-technologies
Geode-capital-management
Tonix-pharmaceuticals-holding-corp
Tonix-pharmaceuticals-trading-down
Virtu-financial
Nasdaq
News-ratings-for-tonix-pharmaceuticals-daily
Tonix-pharmaceuticals
Hedge-funds-weigh-in-on-tonix-pharmaceuticals
Tonix-pharmaceuticals-company-profile

Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Free Report) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the stock. Separately, Dawson James assumed coverage on Tonix Pharmaceuticals in a report on Wednesday, February 28th. They set a buy rating and a $3.00 target […]

Dawson-james
Zembrace-symtouch
Tonix-pharmaceuticals-holding-corp
Jpmorgan-chase-co
Tonix-pharmaceuticals-price-performance
News-ratings-for-tonix-pharmaceuticals-daily
Hedge-funds-weigh-in-on-tonix-pharmaceuticals
Raymond-james-associates
Tonix-pharmaceuticals
Virtu-financial
Free-report
Sigma-investments

Tonix Pharmaceuticals (NASDAQ:TNXP) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Free Report) in a research note released on Tuesday. The brokerage issued a sell rating on the stock. Separately, Dawson James started coverage on Tonix Pharmaceuticals in a report on Wednesday, February 28th. They set a buy rating and a $3.00 price target for the […]

Dawson-james
Zembrace-symtouch
Tonix-pharmaceuticals-holding-corp
Sabby-management
Geode-capital-management
Institutional-investors-weigh-in-on-tonix-pharmaceuticals
Tonix-pharmaceuticals-stock-down
Tonix-pharmaceuticals
Jpmorgan-chase-co
Tonix-pharmaceuticals-company-profile
News-ratings-for-tonix-pharmaceuticals-daily
Armistice-capital

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.